Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
Deals
Features
News
Region
Sectors
Size

$40m-$99.9m

Alentis accesses $67m series B
Morningside Venture Investments has led a series B round for the fibrotic diseases-focused spinout that advances University of Strasbourg research.
QitanTech keeps pace through $63m series B
The Tsinghua-backed DNA and RNA sequencing equipment manufacturer has added $63m to its coffers.
Tata Digital works out $75m for CureFit
Tata Digital has hired CureFit’s chief executive as part of a $75m investment for the UC-RNT Fund-backed health and fitness app developer.
Iksuda seals $47m investment
IP Group sold a $5m stake to incoming shareholder Celltrion as part of a series A round for Iksuda, a spinout of Bath originally called Glythera.
LeoLabs makes space for $65m series B
The low Earth orbit mapping technology provider has raised more than $100m altogether, having picked up series A financing from Weru Investment in 2018.
Stablix surfaces with $63m series A
Stablix Therapeutics has launched with $63m in equity financing to commercialise research pioneered in Henry Colecraft’s laboratory at Columbia University.
Pulmocide picks series C investors
IP Group has participated in a $92m series C round for Pulmocide, a developer of treatments for respiratory diseases that was spun out of Imperial College London.
AkroStar collects $78m series A
Respective endowments for University of Macau and Macau University of Science and Technology have contributed to a series A round.

Other News

Huisuanzhang hauls in $80m
Undisclosed investors have supplied series D funding for the Tsinghua-backed bookkeeping and taxation software developer.
Vedere Bio II sees light in $77m series A
The UC Berkeley spinout-derived genetic eye disease therapeutics company has launched with fresh funding featuring new and founding investors.
Interius initiates $76m series A
UPenn, Penn Medicine and OUP all contributed to an oversubscribed series A round for UPenn spinout Interius Biotherapeutics.
Bluestar shoots to $70m series C
Based on research at Stanford, Bluestar Genomics is working on a non-invasive test for pancreatic cancer.
Appia Bio appears with $52m series A
Appia Bio has emerged from stealth with $52m in series A financing to commercialise cancer treatments based on research at UCLA.
Kin constructs series C
UChicago once again invested in Kin Insurance, participating in a $63.9m series C round that brought its overall funding to nearly $150m.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg

Login